Galectin Therapeutics
GALT
60 hedge funds and large institutions have $14.8M invested in Galectin Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 6 closing their positions.
523% more call options, than puts
Call options by funds: $187K | Put options by funds: $30K
84% more capital invested
Capital invested by funds: $8.05M → $14.8M (+$6.78M)
0.1% more ownership
Funds ownership: 11.97% → 12.07% (+0.1%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
2% less funds holding
Funds holding: 61 → 60 (-1)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WANY
Wealthspire Advisors (New York)
New York
|
+$297K |
| 2 |
Morgan Stanley
New York
|
+$242K |
| 3 |
IAA
Independent Advisor Alliance
Charlotte,
North Carolina
|
+$58.3K |
| 4 |
HKAM
Horizon Kinetics Asset Management
New York
|
+$48.4K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$31.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$209K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$133K |
| 3 |
VF
Virtu Financial
New York
|
-$44K |
| 4 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$40.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$27.3K |
GALT Hedge Fund Activity: Q1 2023 in Review
60 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2023, worth a combined $14.8M — up 84% from $8.05M a quarter earlier.
Fund positioning in GALT was balanced in Q1 2023: 6 funds opened new positions, 6 closed out, 9 added to existing stakes and 15 trimmed.
The largest buyer was Wealthspire Advisors (New York), opening a new position worth an estimated $297K. The largest seller was Millennium Management, cutting an estimated $209K.
- 60 institutional investors held Galectin Therapeutics (GALT) as of Q1 2023, down from 61 in Q4 2022.
- Funds reported $14.8M of Galectin Therapeutics stock for Q1 2023, up 84% quarter-over-quarter.
- 6 funds opened new Galectin Therapeutics positions in Q1 2023 and 6 closed out, a net change of 0 holders.
- The largest Galectin Therapeutics buyer in Q1 2023 was Wealthspire Advisors (New York), an estimated $297K added.
- The largest Galectin Therapeutics seller in Q1 2023 was Millennium Management, an estimated $209K sold.
Based on aggregated 13F filings for Q1 2023.